Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

NEC.3 (Alliance 021202), A Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumours, was closed to accrual on October 7, 2016.

Final accrual was 171, of which Canada randomized 25 patients.

Thank you to all member centres, staff and patients for participating in this study.